ASSEMBLY BIOSCIENCES INC (ASMB)

ASMB Stock Earnings: Assembly Biosciences Beats EPS for Q4 2023

ASMB stock results show that Assembly Biosciences beat analyst estimates for earnings per share the fourth quarter of 2023.

ASMB Stock Earnings: Assembly Biosciences Beats EPS for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Assembly Biosciences (NASDAQ:ASMB) just reported results for the fourth quarter...

Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlights

Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlights

Four candidates planned to be in clinical development in 2024 with interim data from two studies anticipated by year end Clinical development timelines...

ASMB Stock Earnings: Assembly Biosciences Misses EPS for Q2 2023

ASMB stock results show that Assembly Biosciences missed analyst estimates for earnings per share the second quarter of 2023.

ASMB Stock Earnings: Assembly Biosciences Misses EPS for Q2 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Assembly Biosciences (NASDAQ:ASMB) just reported results for the second quarter...

Assembly Biosciences announces effective date of reverse stock split (NASDAQ:ASMB)

Assembly Biosciences announces a reverse stock split to bring the company into compliance with Nasdaq listing requirements.

Assembly Biosciences Announces Effective Date of Reverse Stock Split

Assembly Biosciences Announces Effective Date of Reverse Stock Split

– Assembly Bio common stock expected to begin trading on a split-adjusted basis on February 12, 2024 – SOUTH SAN FRANCISCO, Calif., Feb. 08, 2024 ...

Assembly Biosciences Provides Anticipated Development Milestones for 2024

Assembly Biosciences Provides Anticipated Development Milestones for 2024

Four development candidates anticipated to be in the clinic by the end of 2024, reflecting expansion of R&D portfolio across herpesviruses and...

Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative...

Assembly Biosciences Presents New Data Highlighting Viral Hepatitis Portfolio at AASLD The Liver Meeting®

Assembly Biosciences Reports Third Quarter 2023 Financial Results and Recent Updates

Assembly Biosciences names Gaggar as its chief medical officer (NASDAQ:ASMB)

Assembly Biosciences appoints Anuj Gaggar, MD, PhD as Chief Medical Officer, bringing his experience from his role as CEO at Arrive Bio.

Assembly Biosciences Names Anuj Gaggar, MD, PhD, as Chief Medical Officer

Assembly Biosciences Names Anuj Gaggar, MD, PhD, as Chief Medical Officer

-- Dr. Gaggar is an experienced industry executive with substantial infectious disease expertise and proven record of successfully leading early- and...

Why Are Stocks Down Today?

Stocks are down today, and investors wondering why are in the right place as we have all the details they need to know about on Tuesday!

Why Is Assembly Biosciences (ASMB) Stock Up 92% Today?

Assembly Biosciences stock is taking off with heavy trading of ASMB shares after the company announced a new collaboration agreement!

Assembly Bio stock surges on deal with Gilead (NASDAQ:ASMB)

Assembly Biosciences (ASMB) shares surge 137% after partnering with Gilead Sciences (GILD) to develop antiviral therapies. Read more here.

Gilead and Assembly Biosciences Establish Partnership to Develop Next-Generation Therapeutics for Serious Viral Diseases

Assembly Biosciences to Present New Data at AASLD The Liver Meeting®

Assembly Biosciences to Present New Data at AASLD The Liver Meeting®

-- One poster and one oral presentation selected, with the poster highlighting new preclinical data from the Company’s interferon-α receptor agonist...

Assembly Biosciences Nominates Development Candidate ABI-6250, an Orally Bioavailable HDV Entry Inhibitor

Assembly Biosciences Nominates Development Candidate ABI-6250, an Orally Bioavailable HDV Entry Inhibitor

− ABI-6250 demonstrated low nanomolar potency against hepatitis D virus and selective inhibition of NTCP in preclinical studies with once-daily dosing...